SEC Form 4 Filing for Fennec Pharmaceuticals Inc.

This filing reports on the transactions of Sayad Pierre Sargis, Chief Medical Officer of Fennec Pharmaceuticals Inc. On August 31, 2026, Mr. Sargis acquired 168 common shares, which were released from restriction from shares awarded on March 28, 2025. Following this acquisition, he sold 12,000 common shares at a price of $12.18 per share. These shares were previously vested restricted shares and vested performance shares. After these transactions, Mr. Sargis directly owns 9,519 shares of Fennec Pharmaceuticals Inc. common stock. The transactions were reported on a Form 4 filing.